A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

被引：0
|
作者：
Daver, Naval G. [1 ]
Vyas, Paresh [2 ]
Xing, Guan [3 ]
Renard, Camille [3 ]
Bagheri, Taravat [3 ]
Curtis, Kelly [3 ]
Sallman, David A. [4 ]
Wei, Andrew H. [5 ,6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Weatherall Inst Mol Med, Oxford, England
[3] Gilead Sci Inc, Foster City, CA USA
[4] Moffitt Ctr Canc, Tampa, FL USA
[5] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] Eliza Hall Inst Med Res, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
AML; magrolimab; azacitidine; ENHANCE-2; anti-CD47; Trial-in-Progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-554
引用
收藏
页码：S312 / S312
页数：1
相关论文
共 50 条
  • [1] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark P.
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S6
  • [2] A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia
    Daver, Naval
    Vyas, Paresh
    Chao, Mark
    Xing, Guan
    Renard, Camille
    Ramsingh, Giri
    Sallman, David A.
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [3] A Phase III, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy (ENHANCE-3)
    Daver, Naval G.
    Liu, Ke
    Kuwahara, Sowmya B.
    Caldwell, Kenneth
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S313 - S314
  • [4] Phase 1b/2 Combination Study of APR-246 and Azacitidine in Patients With TP53-Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
  • [5] Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study
    Roboz, Gail J.
    Pabst, Thomas
    Aribi, Ahmed
    Brandwein, Joseph M.
    Dohner, Hartmut
    Fiedler, Walter
    Gandini, Domenica
    Geddes, Michelle
    Hou, Jing-Zhou
    Howes, Angela J.
    Hultberg, Anna
    Huselton, Eric
    Jacobs, Julie
    Kane, Colleen
    Lech-Maranda, Ewa
    Louwers, Marieke
    Nottage, Kerri
    Platzbecker, Uwe
    Rampal, Raajit
    Salman, Mariya
    Shah, Priya
    Stevens, Don
    Stuart, Monic
    Subklewe, Marion
    Sumbul, Anne
    Wang, Eunice S.
    Wierzbowska, Agnieszka
    Yao, Bin
    Yee, Karen
    Kantarjian, Hagop
    Borthakur, Gautam
    BLOOD, 2021, 138
  • [6] Nature of Clinical Response and Depth of Molecular Response in Patients With TP53-Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated With Magrolimab With Azacitidine
    Johnson, Lisa
    Zhang, Yajia
    Li, Biao
    Aviles, Lisa
    Daver, Naval G.
    Vyas, Paresh
    Sallman, David A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S362 - S362
  • [7] A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)
    Daver, Naval
    Liu, Ke
    Werneke, Scott
    Rustia, Evelyn
    Ramsingh, Giri
    Vyas, Paresh
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S5
  • [8] Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Goldberg, Aaron D.
    Winer, Eric S.
    Altman, Jessica K.
    Fathi, Amir T.
    Odenike, Olatoyosi
    Roboz, Gail J.
    Gallacher, Phillip
    Wennborg, Anders
    Hickman, Denice Kaylor
    Attar, Eyal C.
    Sallman, David A.
    BLOOD, 2021, 138
  • [9] Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
    DiNardo, Courtney L.
    Pratz, Keith W.
    Letai, Anthony
    Jonas, Brian A.
    Wei, Andrew H.
    Thirman, Michael
    Arellano, Martha
    Frattini, Mark G.
    Kantarjian, Hagop
    Popovic, Relja
    Chyla, Brenda
    Xu, Tu
    Dunbar, Martin
    Agarwal, Suresh K.
    Humerickhouse, Rod
    Mabry, Mack
    Potluri, Jalaja
    Konopleva, Marina
    Pollyea, Daniel A.
    LANCET ONCOLOGY, 2018, 19 (02): : 216 - 228
  • [10] Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
    Daver, Naval
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Boddu, Prajwal C.
    Alfayez, Mansour
    Cortes, Jorge E.
    Konopleva, Marina
    Ravandi-Kashani, Farhad
    Jabbour, Elias
    Kadia, Tapan
    Nogueras-Gonzalez, Graciela M.
    Ning, Jing
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Andreeff, Michael
    Pierce, Sherry A.
    Gordon, Tauna
    Kornblau, Steven M.
    Flores, Wilmer
    Alhamal, Zainab
    Bueso-Ramos, Carlos
    Jorgensen, Jeffrey L.
    Patel, Keyur P.
    Blando, Jorge
    Allison, James P.
    Sharma, Padmanee
    Kantarjian, Hagop
    CANCER DISCOVERY, 2019, 9 (03) : 370 - 383
12345